Zurich medtech and biotech crossing into the US: what actually needs to land first.

The typical Zurich medtech or biotech owner arriving at the US.

The archetype is specific and recurring. A Zurich medtech firm with a Swissmedic-cleared device and a growing European installed base is building a US commercial motion, typically after a first US customer pilot has landed or a first US hire has been placed. A Zurich or Basel-adjacent biotech owner is carrying a pipeline asset through late preclinical or early clinical stages with strong Swiss academic grounding and credible IP, now scoping the US as the commercialisation geography where the asset will either cross the clinical threshold or be partnered. A Zurich diagnostics or digital-health platform with several European reference accounts is beginning US market evaluation. In each case the home-market work is real and the assets are credible. The question is not whether GMA has something worth bringing to the US. It is whether the US-facing presentation of what GMA has is constructed in the register the US buyer is filtering on.

The Zurich and Basel biotech cluster itself is a material asset. Proximity to ETH, the University of Zurich, the University Hospital, and the Basel pharma base creates a scientific ecosystem and a credible recruitment and collaboration environment that US counterparties recognise when it is surfaced correctly. The caveat is in the last phrase. Cluster adjacency is an asset the US buyer acknowledges once the US sales story is in front of it. Placed in the lead position, the cluster signal lands as academic context rather than as a commercial proposition. The same fact, placed differently, produces two different evaluations.

What US buyers notice first is the shape of the commercial claim. The Swiss medtech or biotech owner whose US-facing materials open with Swissmedic cleanliness, academic publications, and Zurich-Basel heritage is making a claim about GMA's scientific and regulatory quality. That claim is not wrong. It is, in the American sales story, the wrong first claim. The US buyer path that works opens on the US category the company competes in, the US customer segment it serves, and the US outcome the customer or investor should expect. Scientific and regulatory quality then carry as supporting proof.

What US KOLs, payers, commercial partners, and biotech GPs actually filter on.

The filter differs by buyer. US KOLs in a therapeutic area filter on US clinical references in the same indication or adjacent indications, US-side investigator relationships, US-site trial activity, and publications in the US-evaluate journals the KOL community pays attention to. A Zurich biotech arriving at a US KOL with strong Swiss and European publications but no US-side investigator relationship is asking the KOL to accept GMA's credibility on the European record alone. Some KOLs will do that work. Most will not, because the US filter is calibrated by repeated comparison to US-present peers who arrive with the US-side proof stack already assembled. a company that assembles the US-side proof stack before the first KOL meeting advances. a company that does not defers the KOL conversation and the clinical relationships that follow from it.

US payers filter on US reimbursement pathway feasibility, US coverage precedent in the same or adjacent category, US health-economic evidence structured for US commercial and government payer evaluation, and US clinical-outcome endpoints that match the US payer's evaluation frame. A Zurich medtech firm with a clean Swiss reimbursement story and strong European health-economic data is making a case the US payer cannot directly apply. The US payer needs the equivalent frame constructed in US terms. This is not GMA's core commercial job in the home market, and the absence of US-facing health-economic framing is not a deficiency of GMA. It is an absence the US sales story needs to surface and address deliberately.

US commercial partners (strategic buyers, large medtech platforms, US GPOs, US specialty distributors) filter on US commercial scale potential, US commercial footprint, US customer-base fit with the partner's existing coverage, and US channel economics. They are making a resource-allocation decision against other inbound partnership conversations and against internal build-versus-partner evaluations. A Zurich firm whose US buyer path does not name US commercial scale at US-market-size is asking the US commercial partner to infer the scale from the European-tier numbers. The commercial partner will not do the inference. The Zurich firm that arrives with US-scale framing stated explicitly converts the meeting from a due-diligence conversation into a specific partnership conversation.

US biotech GPs filter on US-side clinical activity, US-side investigator and KOL access, US-side pipeline legibility, US peer comparables at the stage the company sits in, US regulatory interaction history, and the US commercial trajectory the GP can model. The Zurich biotech owner whose US-facing deck opens with Swiss scientific pedigree and cluster adjacency is asking the GP to do the US-side translation on behalf of GMA. The GP does not have the time or the incentive to do that work. The deck that opens on the US category, the US peer set, and the US commercial trajectory advances. The deck that opens on Swiss science does not, no matter how strong the science itself.

US KOLs, US payers, US commercial partners, and US biotech GPs are each filtering on US-side proof stacks. The Swiss commercial story is credible. It is also not what the US buyer is filtering for. The fix is to put the US proof stack at the front, and let the Swiss credibility carry beneath. House view on Zurich medtech and biotech US entry

Three signal gaps specific to Zurich medtech and biotech.

Swiss compliance as non-commercial signal. The first gap. Swissmedic cleanliness, Swiss GMP certification, EMA pathway history, and FINMA-adjacent regulatory posture are presented in the US-facing materials as primary trust signals. In the Swiss and European frame this is the correct register: regulatory cleanliness is a foundational trust signal because the home audience assumes commercial viability is in GMA's operational control. The American commercial buyer inverts the hierarchy. Regulatory cleanliness is assumed. It judges in the US as administrative hygiene: necessary, not differentiating. When the US buyer path leads on regulatory cleanliness without a US commercial claim in front of it, the American buyer interprets the lead as an absence of commercial positioning rather than as regulatory credibility. The correction is to surface Swiss regulatory cleanliness as supporting proof inside a US sales story, with the US category and US customer outcome in the lead position.

Academic-rigour bios that do not travel. The second gap. Owner bios built around Swiss academic credentials, ETH or University of Zurich positioning, University Hospital affiliations, publication counts, and European research-network standing do not index against the US KOL, US biotech GP, or US commercial partner reference frame. The US buyer is sorting bios for US-side signals: US category track record, US-side commercial-scale operating experience, US-board or US-specialist positions, US KOL or US investigator relationships, US commercial wins, and US fundraising history. A Zurich medtech or biotech owner whose bio is constructed in the Swiss academic register is asking the US buyer to accept the academic record as commercial proof. The buyer does not perform that conversion. The correction rebuilds the US-facing owner/CEO bios for the US peer set: US-category specifics, US-side relationships, and US commercial experience surfaced where it exists, with academic heritage held as supporting context. The home bio continues to run in the Swiss academic register for Swiss and European audiences.

Outcome claims understated. The third gap. Swiss commercial culture prefers capability statements to outcome claims. the company is described in terms of what it builds, what it develops, and what it specialises in, rather than in terms of the commercial result the US customer or US investor should expect. In the Swiss frame the understatement is a trust signal: GMA is credible because it does not overclaim. In the US frame the understatement lands as hedged conviction and unconfirmed commercial traction. The US buyer interprets the absence of an outcome claim as the absence of an outcome, not as cultural restraint. The correction moves the outcome claim to the front, stated in US-legible terms (US commercial traction, US customer wins, US clinical evaluate-outs, US revenue scale, US pipeline milestones), with the capability description held as supporting evidence that the outcome is delivered reliably.

Vertical lens: medtech and biotech primary, engineering-commercial adjacent.

The pattern is consistent across the Zurich medtech and biotech base, with surface-level differences worth noting. Medtech carries the US commercial-partner and US health-system filter most visibly: US procurement officers, US GPO decision-makers, US hospital-system evaluators, and US payer-evaluation committees are the immediate audience. The US buyer path needs the US category, US customer type, and US installed-base or commercial-scale claim named directly. Swiss commercial scale stays as context; US scale carries the lead. Biotech carries the US KOL, US biotech GP, and US strategic-partner filter. The US buyer path needs the US clinical pathway, US peer set, US commercial trajectory, and US-side relationships named directly. Swiss scientific credibility stays as supporting context. Engineering-commercial firms adjacent to medtech and biotech (Zurich engineering groups building devices, diagnostics, lab automation, or clinical-workflow systems) carry the same signal pattern with the additional layer of engineering-specification-heavy materials replacing commercial positioning. The correction is parallel: move the commercial claim to the front and hold the engineering specification as supporting proof, not the lead. Family-office-backed holdings carrying medtech or biotech operating companies inherit the same signal gaps at the holding level and need the holding brand and the operating brand aligned on a single US-sales story.

The fix sequence.

Three stages in order. The order matters. Rebuilding materials on a broken story produces cleaner execution on the same mis-score.

Evaluate. The first stage identifies which of the three signal gaps is breaking first in the specific firm's US buyer path. The evaluation is firm-specific. A Zurich medtech at US-KOL stage with no US investigator relationships has a different first break than a Zurich biotech at US-GP fundraising stage. The evaluation pages and sales materials where the US conversations are going quiet (the KOL who does not return the email, the US payer meeting that does not advance to a second meeting, the US biotech GP who takes the first call and does not schedule the follow-up), what US buyers are encountering in the first ninety seconds of the materials, and which of the three gaps is doing the damage. The evaluation is the foundation of the rebuild, not a deliverable in its own right.

Correct the signal. The second stage rebuilds the US buyer path. The US category is named at the front with the US customer type and the US outcome. The US commercial claim is stated directly in US-legible terms. Swiss regulatory cleanliness, academic credibility, and cluster adjacency are repositioned as supporting proof beneath. Owner bios are rebuilt for the US peer set. Outcome claims are moved from capability language to result language. The home materials continue in the Swiss sales language for Swiss audiences. The US website, deck, and sales material is rebuilt in parallel, not as a translation of the home materials but as a purpose-built frame for the US buyer.

Rebuild the execution layer. The third stage rebuilds the pages and sales materials the US buyer sees. US-KOL-facing materials, US payer-facing health-economic framings, US commercial-partner decks, US biotech GP decks, US investigator and clinical-site materials, US-facing site and sales system, and the US commercial cadence of the US-facing team. The execution layer sits on top of the corrected story. Done last, it produces materials that survive the US filter. Done first, it produces beautifully executed materials that repeat the original mis-score with higher fidelity.

When to engage us.

GMA runs three engagements for Zurich medtech and biotech owners. GMA confirms fit and pricing after the inquiry screening. Public prices are not listed.

• Market-Entry Marketing Sprint (six to ten weeks) for a single US category correction and the first US-facing materials rebuilt and shipped. Typical for a Zurich medtech or biotech owner at the first US KOL or first US-investor stage. See the Sprint →
• Cross-Border Marketing Build (three to six months) for a full US rebuild across positioning, US-KOL and US-payer materials, US biotech GP decks, US-facing site, and US commercial cadence. Standard shape for Zurich medtech and biotech owners committed to US commercialisation. See the Build →
• Global Marketing Partnership (monthly retainer, twelve-month minimum) for Zurich family-office-backed holdings with multiple medtech or biotech operating brands requiring US-facing rebuilds in parallel. See the Partnership →

For the wider Zurich corridor gate, see the Zurich city page. For the family-office page inside the Zurich corridor, see the Zurich family-office page. For the specific register-translation problem in deeper detail, see Swiss discretion vs US visibility.

Frequently asked questions.